Outsourcing

Experts from Baxter BioPharma Solutions provided the following commentary on trends in bio/pharmaceutical development outsourcing.

Annual study shows geographic proximity not a factor in CMO selection.

John Sandles, Business Analyst for Fujifilm Diosynth Biotechnologies, provided commentary on the evolving role of contract services in biologics drug development and manufacturing.

Changing regulations are impacting the identification and monitoring of variable materials in excipients.

Biopharma manufacturers must reduce the risk in their complex supply chains

Annual study shows CMO technical expertise is not enough.

Shrinking facility size, growth of biologics, and emerging market demand influence pharma investments.

Developments in chromatography column technology to deliver greater efficiency, speed and inertness benefit the drug development process from discovery to manufacturing and quality control.

Eric Langer of BioPlan Associates describes the development of biopharmaceutical outsourcing in Europe over the past 25 years.

Contract research, development, and manufacturing organizations invested in new facilities and technologies in 2014 for analytical testing, as well as small- and large-molecule drug development.

Contract service providers describe how quality by design has influenced a drug sponsor's expectations of suppliers.

Evolving clinical trial research services give biopharmaceutical companies options for full and functional services.

Representatives of contract service organizations that develop biologic-based drugs discussed technology trends such as high-throughput screening and single-use systems.

Experts from contract testing laboratories and service organizations shared their perceptions of analytical testing advances, and challenges still ahead.

Contract services ride high as funding floods bio/pharma.

Representatives of contract service organizations that specialize in parenteral drug development and manufacturing describe the evolving trends.

Despite the growth of specialist companies with capabilities across various therapeutic areas in Europe, there is still a need for early development expertise with end-to-end pharmaceutical manufacturing capabilities.

Contract development and manufacturing organizations identify trends, challenges, and emerging technology and service needs for solid and semi-solid dosage forms.

For a bio/pharma industry in flux, contract services are playing a greater-and more diverse-role in drug development.

Packaging Coordinators, Inc. expands its services with acquisition of Penn Pharmaceutical Services.

Hovione will use Merrion's GIPET absorption-enhancing technology for solid-dosage drugs.

As payers refuse to cover new drugs, CMOs take a hit.

PharmSource special report shows demand for cytotoxic injectable drugs could tap existing CMO capacity.

With budgets growing, clients see CMOs' costs as less crucial.

Paul Nelles of Vetter Development Service discusses prefilled syringes.

DCAT's Sharp Sourcing 2014 educational program offers pharmaceutical and biopharmaceutical companies a forum to gain best practice insights in sourcing and procurement.

Industry experts discuss how extractables and leachables studies are designed using a risk-based approach.

Data integrity in the analytical laboratory is an area of increasing focus for regulators such as FDA.

The CMO industry's value proposition is limiting its market penetration.

Biopharma companies should not overlook India's growing market.